Aragen Building $30M Biomanufacturing Site in India

Aragen, a contract research development and manufacturing organization (CRDMO) for small molecules and biologics, is setting up a new biologics manufacturing facility in Bangalore, India.

The facility is part of a $30 million investment, spanning nearly 160,000 square meters, and includes process development labs and multiple GMP manufacturing suites with supporting functions like quality control labs (analytical and microbiology). The manufacturing suites will be equipped for intensified processing using single-use bioreactors and advanced downstream purification capability to serve it’s biologics customer base.  

In addition, the facility will offer integrated services from process development, process validation, analytical development, pilot production, large-scale DS manufacturing and stability services. It will have the capability to develop and manufacture mAbs, therapeutic proteins and fusion proteins to augment the company’s bioproduction capability in California.

The process development lab is scheduled to be operational by 3Q24 while the first manufacturing suite will open in the 3Q25. The facility is designed to include plasmid DNA, mRNA, cell and gene therapy, microbial manufacturing and additional GMP manufacturing suites in the future as demand ramps up.
 
Manni Kantipudi, CEO, Aragen Life Sciences said, “Setting up of a biologics manufacturing facility in India is part of our forward integration strategy for our US-based biologics business, allowing Aragen to offer integrated gene-to-GMP solutions to our customers. Once this facility is commissioned, Aragen will offer a unique value proposition to our biologics customers where the early-stage discovery will be executed in our R&D labs in California, where we have access to the top scientific talent and have proximity to our customers.  As the molecule advances, Aragen can tech-transfer the program to our world-class manufacturing facility in Bangalore, offering better COGS to our customers.”

Aragen, through its subsidiary, Aragen Bioscience Inc., offers a range of in vitro and in vivo services for the discovery, cell line development, production, characterization and efficacy assessment and development of biologics for human and animal health, with R&D facilities in the San Francisco Bay area.